To improve the outcomes of postmenopausal women with early-stage breast cancer is an important ongoing research goal. In The Lancet Oncology, Marco Colleoni and colleagues¹ of the International Breast Cancer Study Group attempted to address this important research question in the Study Of Letrozole Extension (SOLE) trial in which they evaluate a novel approach to aromatase inhibitor administration—namely, extended intermittent use of adjuvant letrozole. At 5 years' follow-up, they report that disease-free survival did not differ significantly between women who received extended intermittent letrozole and those given continuous letrozole (hazard ratio 1·08, 95% CI 0·93–1·26; p=0·31).

中文翻译：

---

间歇性来曲唑辅助治疗的复杂性

改善绝经后早期乳腺癌妇女的预后是一项重要的正在进行的研究目标。在《柳叶刀肿瘤》杂志上，国际乳腺癌研究小组的Marco Colleoni及其同事¹试图在Letrozole延伸研究（SOLE）试验中解决这个重要的研究问题，在该试验中，他们评估了芳香化酶抑制剂管理的一种新方法，即延长间歇性给药佐剂来曲唑的使用。在随访的5年中，他们报告说，接受长期间歇性来曲唑治疗的妇女和接受连续来曲唑治疗的妇女的无病生存率没​​有显着差异（危险比1·08，95％CI 0·93-1·26； p = 0·31）。